Cargando…

A pilot study on area under curve of mycophenolic acid as a guide for its optimal use in renal transplant recipients

BACKGROUND & OBJECTIVES: The immunosuppressants administered to renal transplant subjects are usually monitored therapeutically to prevent graft rejection and drug toxicity. Mycophenolic acid (MPA) is an immunosuppressant. The present prospective study was undertaken to establish the utility of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarangi, S.C., Reeta, K.H., Agarwal, S.K., Kaleekal, T., Guleria, S., Gupta, Y.K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307190/ https://www.ncbi.nlm.nih.gov/pubmed/22382188 http://dx.doi.org/10.4103/0971-5916.93429

Ejemplares similares

Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium
por: Jia, Yichen, et al.
Publicado: (2017)

The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients
por: AbdElhalim, Mohamed S., et al.
Publicado: (2020)

A limited sampling strategy for estimation of the area under the curve (0 to 8 hours) of mycophenolic acid administered three times daily to liver transplant recipients
por: Marcos, Bernardino, et al.
Publicado: (2011)

Effect of Mycophenolate Mofetil on Plasma Bioelements in Renal Transplant Recipients
por: Kamińska, Jolanta, et al.
Publicado: (2011)

Usefulness of limited sampling strategy for mycophenolic acid area under the curve considering postoperative days in living-donor renal transplant recipients with concomitant prolonged-release tacrolimus
por: Enokiya, Tomoyuki, et al.
Publicado: (2017)

Mycophenolic acid area under the curve recovery time following rifampicin withdrawal
por: Annapandian, V. M., et al.
Publicado: (2010)

Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention
por: Metz, David K., et al.
Publicado: (2014)

Celiac-like Enteropathy Associated With Mycophenolate Sodium in Renal Transplant Recipients
por: Filiopoulos, Vassilis, et al.
Publicado: (2018)

Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy
por: Hwang, Shin, et al.
Publicado: (2017)

Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients
por: Zhang, Jun, et al.
Publicado: (2017)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study
por: Bremer, Sara, et al.
Publicado: (2009)

Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients
por: Sunder-Plassmann, Gere, et al.
Publicado: (2012)

A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients
por: Kim, Jong Man, et al.
Publicado: (2014)

Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients
por: Zhang, Jun, et al.
Publicado: (2018)

Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient—No Intervention Actually Needed
por: Åsberg, Anders, et al.
Publicado: (2020)

Orthotopic Heart Transplant Recipient with Enteric-coated Mycophenolate Sodium (Myfortic) Induced Colitis
por: Morris, Craig C., et al.
Publicado: (2020)

Mycophenolate mofetil increases the risk of diarrhea in allogeneic hematopoietic stem cell transplantation recipients
por: Lin, Liangmo, et al.
Publicado: (2023)

Transplant Prognosis in Kidney Transplant Recipients with Diabetes under Mycophenolic Acid-Focused Therapeutic Drug Monitoring
por: Nakamura, Eisuke, et al.
Publicado: (2021)

Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms
por: Pithukpakorn, Manop, et al.
Publicado: (2014)

NOTTO COVID-19 Vaccine Guidelines for Transplant Recipients
por: Kute, Vivek B, et al.
Publicado: (2021)

Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact
por: Agrawal, A., et al.
Publicado: (2016)

Human cytomegalovirus glycoprotein N polymorphisms among renal transplant recipients in India
por: Patro, A Raj Kumar, et al.
Publicado: (2014)

Pharmacokinetics of mycophenolic acid and its phenyl glucuronide metabolite in kidney transplant recipients with renal impairment
por: Kamińska, Jolanta, et al.
Publicado: (2012)

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients
por: de Winter, Brenda C. M., et al.
Publicado: (2009)

Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient
por: Hasan, Ashfaq, et al.
Publicado: (2014)

Serum Selenium, Iron, Zinc, and Copper Concentrations in Renal Transplant Recipients Treated with Mycophenolate Mofetil
por: Wilk, Aleksandra, et al.
Publicado: (2020)

Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients
por: Jung, Hee-Yeon, et al.
Publicado: (2020)

Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients
por: Hennes, Anthony J., et al.
Publicado: (2020)

Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients
por: Xiang, Hongping, et al.
Publicado: (2021)

Estimation of Mycophenolic Acid Exposure in Heart Transplant Recipients by Population Pharmacokinetic and Limited Sampling Strategies
por: Wang, Xipei, et al.
Publicado: (2021)

HIV associated renal disease: A pilot study from north India
por: Gupta, Vijay, et al.
Publicado: (2013)

Mycophenolate mofetil-induced oral ulcerations in solid organ transplant recipients: A report of 3 cases
por: Salik, Jonathan, et al.
Publicado: (2015)

Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients
por: Brunkhorst, Lena Caroline, et al.
Publicado: (2015)

Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients
por: Drevland, Ole Martin, et al.
Publicado: (2023)

ISOT Consensus Statement for the Kidney Transplant Recipient and Living Donor with a Previous Diagnosis of COVID-19
por: Kute, Vivek B., et al.
Publicado: (2022)

Effect of clinical condition and mycophenolate mofetil on plasma retinol, α-tocopherol and β-carotene in renal transplant recipients
por: Kamińnska, Jolanta, et al.
Publicado: (2012)

Prospective Controlled Protocol for Three Months Steroid Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients
por: Oh, Chang-Kwon, et al.
Publicado: (2012)

Comparison of PETINIA and LC-MS/MS for determining plasma mycophenolic acid concentrations in Japanese lung transplant recipients
por: Kikuchi, Masafumi, et al.
Publicado: (2018)

Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report
por: Chen, Dong, et al.
Publicado: (2020)

Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients
por: Piyasiridej, Sudarat, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i8rrocu7bi91g3403q0ju908bm